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Tumor growth models are important to create an engineering background for cancer treatment either by using the models for
simulations and evaluation of treatment protocols or, if combined with control engineering, by designing treatment protocols. A
well-defined tumor growth model must describe the physiological processes and the measurements as well. Growing tumors are
composed of dead tumor cells (forming the necrotic part) and living, proliferating tumor cells (forming the proliferating part);
when tumor volume is measured, these parts are measured together. Most of the known tumor growth models do not consider
the modeling of the necrotic part. Starting from a minimal model of the tumor growth under bevacizumab treatment, the aim of
the current research is to extend it incorporating the volume and dynamics of the necrotic part and the pharmacodynamics and
mixed-order pharmacokinetics of the applied drug.The extendedmodel is validated usingmeasurements with mice as hosts, colon
adenocarcinoma as tumor, and bevacizumab as the drug used for treatment.The results show that the extendedmodel can describe
the important physiological phenomena and shows a good fit to the average of the measurements.
1. Introduction
Angiogenesis, the formation of new blood vessels, is a
fundamental process required for the growth of primary
tumors [1]. Inhibition of angiogenesis is thus a promising
way of fighting against cancer [2, 3]. However, the optimal
protocol for antiangiogenic treatment is still under research
in clinical practice [4].
Application of control theory has been considered in
the literature to give a solution to the dosage problem of
antiangiogenic drugs by many authors; see, for example, [5–
10]. Nevertheless, control engineering methods can only be
applied sufficiently if there is a reliablemodel of tumor growth
that incorporates the effect of the drug. Most of the closed-
loop control approaches in the literature are based on the
Hahnfeldt model [11] or some of its modified versions, for
example, [12]. This model defines the dynamics of the tumor
and the vasculature using a second-order model (without
pharmacokinetics), described by nonlinear differential equa-
tions.
In [13], it was shown that tumor dynamics can be
described by using a simple, first-order model (without
pharmacokinetics) containing a linear and a bilinear term,
where the bilinear term defines the effect of the drug on the
tumor dynamics and ensures positivity of the system. This
model has the ability to explain the experiments in which
mice received one injection and almost every fundamental
physiological process behind tumor dynamics. This minimal
model, which is detailed in Section 2, seems to be a promising
model for the applications, since it has a relatively simple
structure (as opposed to the Hahnfeldt model, its differential
equations contain linear terms and only one bilinear term)
and can be used for controller design purposes as well [14].
However, the model does not incorporate the phe-
nomenon of tumor cell necrosis which is a considerable pro-
cess happening in growing tumors. Tumors have a necrotic
part, composed of dead tumor cells, but the effect of necrotic
cells on tumor growth dynamics is still under investigation.
On the one hand, necrotic cells usually evoke inflammatory
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response which may lead to tumor regression and hence
it could be used for cancer therapy. On the other hand,
necrotic cells stimulate proliferation and angiogenesis (via
tumor necrosis factor) inmost cancer cells, resulting in tumor
promotion. As a consequence, a necrotic region could have
either pro- or antitumor effect [15, 16]. These phenomena
are not known exactly yet, but we can clearly state that
necrotic tumor cells consume space inside the tumor, sowhen
tumor measurement is done, we measure the necrotic and
proliferating tumor cells as well. However, it is important
to separate necrotic tumor volume from the living tumor
volume. Thus, in order to have a more reliable tumor model,
we need to incorporate the effect of tumor necrosis as well.
Moreover, most tumor growth models do not consider
the pharmacodynamics of the drug, that is, the phenomenon
increasing the drug dosage does not necessarily result in
proportional increase in the effect of the drug. The effect of
the drug is considered with Michaelis-Menten kinetics, and
we use mixed-order pharmacokinetic model to describe the
depletion of the drug. In [17] it was shown that the therapy
is much more effective if we give small doses of the drug
each day as opposed to giving a much larger amount at the
beginning of the therapy, regardless of the fact that the drug
depletes slowly.Using themixed-order pharmacokinetics and
the pharmacodynamics in our model, we are able to describe
this phenomenon that could not be described by theminimal
model in [13].
In Section 3, we extend theminimalmodel to incorporate
the effect of tumor necrosis and give a third-order model to
describe the dynamics of proliferating and necrotic tumor
cells and use mixed-order pharmacokinetics and standard
pharmacodynamics to describe the dynamics of the applied
inhibitor. The output of the new model is the sum of the
proliferating and necrotic tumor volumes; we use this output
for parametric identification in Section 4.
We use measurements from experiments with C57Bl/6
mice, using C38 adenocarcinoma as tumor and bevacizumab
as inhibitor [17]. C38 colon adenocarcinoma is a well-known
and widely used mouse tumor, which is originated from
columnar epithelium of colon’s mucosa and has the following
advantages:
(i) it grows fast inmice (after 2-3 weeks it reaches a lethal
size);
(ii) due to its specificity, there is no need to use immuno-
suppressed mice;
(iii) a piece of tumor can be implanted subcutaneously
into the mouse;
(iv) it has large relative vascular area;
(v) it typically does not metastasize;
(vi) tumor cells inflict strong hypoxial reaction.
These properties of the tumor used in the experiments were
favorable for our intentions of creating a simple but descrip-
tive model of tumor growth under the effect of angiogenic
inhibition.
The results show that the proposed model is capable
of explaining the measurements (shows a good fit for the
average of the measurements) while modeling the most
important physiological properties of tumor dynamics as
well.
2. Minimal Tumor Growth Model
A minimal tumor growth model under bevacizumab treat-
ment was proposed in [13] and is further modified to create a
more realistic tumor growth model in the following sections.
The minimal tumor growth model can be explained with
an analogy to chemical reactions. Suppose that the species
𝑋1 represents tumor volume, the species 𝑋2 represents the
inhibitor level, while𝑂 denotes a compartment outside of the
model (we use it to denote inflows and outflows). Then the
model can be regarded as a fictive chemical reaction with the
following equations:
(i) 𝑋1 𝑎󳨀→ 2𝑋1 that defines that the tumor cells proliferate
(divide) with a tumor growth rate 𝑎;
(ii) 𝑋2 𝑐󳨀→ 𝑂 that defines that there is an outflow of the
inhibitor with a reaction rate coefficient 𝑐, that is, the
clearance of the inhibitor;
(iii) 𝑋1 + 𝑋2 𝑏󳨀→ 𝑋2 that defines that if there is inhibitor
(𝑋2) present then the growth of tumor (𝑋1) is
inhibited.
The last equation expresses the inhibitory effect of the applied
drug on tumor growth. Note that this equation defines direct
effect of the drug on the tumor volume; however in the
physiological process, the effect is indirect. This will be
detailed in Section 5. Without proper treatment, the tumor
creates angiogenic signaling molecules, and as a result, the
host body creates dense vasculature around the tumor, and
the tumor grows into that vasculature; thus it has the required
sources of nutrients for proliferation [1]. If the angiogenesis is
inhibited, for example, with the usage of angiogenic inhibitors
(like bevacizumab), the vasculaturewill be less dense; thus the
tumor growth rate will decrease.
The differential equations of the model can be created
based on the chemical reaction equations with techniques,
for example, from [18–20] using mass-action kinetics. The
resulting differential equations and the output of the system
are
?̇?1 = 𝑎𝑥1 − 𝑏𝑥1𝑥2 (1)
?̇?2 = −𝑐𝑥2 + 𝑢 (2)
𝑦 = 𝑥1, (3)
where 𝑥1 denotes the function of tumor volume in mm3, 𝑥2
denotes the function of inhibitor level in mg/kg, 𝑦 is the
output function (that we can measure) in mm3, and 𝑢 is the
input function, the rate of inhibitor injection measured in
mg/(kg⋅day). The model has three parameters, 𝑎 is the tumor
growth rate in 1/day, 𝑏 is the inhibition rate in kg/(mg⋅day),
and 𝑐 is the clearance of the inhibitor in 1/day.
The clearance of intravenous bevacizumab injection is 𝑐
= ln 2/3.9 1/day acquired from [21]. This parameter was not
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tuned for the measurements in [13, 17]; however the other
parameters were identified from mice experiments in [13],
and their values are 𝑎=0.27 1/day and 𝑏=0.0074 kg/(mg⋅day).
This model is a very simple one (containing only one
bilinear term, while all the other terms are linear) that
describes tumor growth under treatment with angiogenic
inhibitor.The novelty of themodel is the differential equation
of the tumor growth that contains a linear and a bilinear term.
The differential equation of the inhibitor is based on the first-
order pharmacokinetic equation of the drug and can be found
in standard literature; see, for example, [11]. The differential
equations define a positive system, that is, if all the initial
conditions are positive, then the solutions of the differential
equations are positive as well.
3. Extended Tumor Growth Model
The tumor growth model discussed in the previous sec-
tion incorporates the fundamental physiological processes
involved in the evolution of tumor volume, that is, the
proliferation of the tumor and the inhibitory effect of the
drug. It was shown in [13] using parametric identification and
validation based on measurements from mice experiments
that the model is also capable of explaining some of the
experimental results as well with some limitations.
There is a fundamental physiological process that is not
modeled in the minimal model: the necrosis of tumor cells.
Necrosis appears in every tumor [1]; thus the measured
tumor volume is the total volume of the proliferating (living)
and necrotic (dead) tumor cells. Since necrotic cells have
important effect on tumor growth; this implies that modeling
the necrotic tumor volume is crucial if we want to create a
valid tumor growth model.
Moreover, the minimal model in [13] is not able to
explain an important phenomenon recognized in [17]. In
[17], it was shown statistically that frequent, small doses of
drug (1/18mg/kg each day, equivalent to 9.5 ⋅ 10−4mg/ml
serum level each day), have significantly larger effect on
tumor growth than one large dose (10mg/kg, equivalent to
0.171mg/ml serum level) at the beginning of the treatment.
The model in [13] was not able to reproduce this result; thus
the model here is modified such that the pharmacodynamics
of the drug is incorporated into the model.
We extend the previously defined model by adding the
dynamics of the necrotic tumor volume and the pharmacody-
namics of the drug. Similar to Section 2, we give the chemical
equivalents of the differential equations with the following
notations: the species 𝑋1 represents the proliferating tumor
volume, the species𝑋2 represents the necrotic tumor volume,
and the species 𝑋3 represents the inhibitor serum level. The
equations of the model are as follows:
(i) 𝑋1 𝑎󳨀→ 2𝑋1 that defines that the tumor cells proliferate
(divide) with a tumor growth rate 𝑎. Using mass-
action kinetics, this equation results in the term ?̇?1 =𝑎𝑥1;
(ii) 𝑋1 𝑛󳨀→ 𝑋2 that defines the necrosis (death) of tumor
cells with necrosis rate 𝑛. Note that this necrosis
is independent of the treatment. Using mass-action
kinetics, this equation modifies the dynamics of the
proliferating and necrotic tumor volumes with the
terms ?̇?1 = −𝑛𝑥1, ?̇?2 = 𝑛𝑥1;
(iii) 𝑋3 𝑐󳨀→ 𝑂 that defines that there is an outflow of the
inhibitor with a reaction rate coefficient 𝑐, that is, the
clearance of the inhibitor. We use Michaelis-Menten
kinetics in order to have a mixed-order model for the
pharmacokinetics, so this equation results in the term
?̇?3 = −𝑐𝑥3/(𝐾𝐵 + 𝑥3), where the parameter 𝐾𝐵 is the
Michaelis-Menten constant of the inhibitor;
(iv) 𝑋1 + 𝑋3 𝑏󳨀→ 𝑋2 that defines that the inhibitor
binds to the angiogenic signaling molecules whose
concentration is proportional to the proliferating
tumor volume; as a result, formation of blood vessels
is inhibited; thus growth of the proliferating tumor
cells is inhibited, and necrosis takes place. The effect
of the inhibition is consideredwithMichaelis-Menten
kinetics withMichaelis-Menten constant ED50 (called
the median effective dose [22]) resulting in the veloc-
ity term 𝑥1𝑥3/(ED50 + 𝑥3). This inhibitory effect on
the volumes is considered with reaction rate coeffi-
cient 𝑏. The effect of this equation on the dynamics
of the proliferating and necrotic tumor volumes is
expressed by the terms ?̇?1 = −𝑏𝑥1𝑥3/(ED50 + 𝑥3) and?̇?2 = 𝑏𝑥1𝑥3/(ED50 + 𝑥3). Since these terms have the
dimension mm3/day, these terms can not be directly
used to modify the dynamics of the inhibitor serum
level, since that has the dimensionmg/(ml⋅day).Thus,
we use the constant 𝜅 with dimension mg/(ml⋅mm3)
to define the term ?̇?3 = −𝜅𝑏𝑥1𝑥3/(ED50 +𝑥3). Instead
of 𝜅, we will use the constant 𝑏𝜅 = 𝜅𝑏 in the remaining
of the paper.
The combination of these terms give the differential equation
of the extended tumor growth model:
?̇?1 = (𝑎 − 𝑛) 𝑥1 − 𝑏 𝑥1𝑥3ED50 + 𝑥3 (4)
?̇?2 = 𝑛𝑥1 + 𝑏 𝑥1𝑥3ED50 + 𝑥3 (5)
?̇?3 = −𝑐 𝑥3𝐾𝐵 + 𝑥3 − 𝑏𝜅
𝑥1𝑥3
ED50 + 𝑥3 + 𝑢, (6)
where 𝑥1 is the time function of proliferating tumor volume
in mm3, 𝑥2 is the time function of necrotic tumor volume
in mm3, 𝑥3 is the time function of inhibitor serum level in
mg/ml, and 𝑢 is the input that is the time function of inhibitor
injection rate in mg/(ml⋅day).
The parameters of the model are listed in Table 1 where
their notations, names, and dimensions are given. The table
also contains the values of the parameters that resulted after
identification which will be detailed in Section 4.
The output 𝑦 of the system is themeasured tumor volume
in mm3 that is the sum of the proliferating (𝑥1) and necrotic
(𝑥2) tumor volumes; that is,
𝑦 = 𝑥1 + 𝑥2. (7)
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Table 1: The parameters of the extended tumor growth model and their values after the identification.
Parameter Parameter name Value Dimension
𝑎 Tumor growth rate 0.4579 1/day
𝑏 Inhibition rate 0.1685 1/day
𝑐 Clearance 0.1825 1/day
𝑛 Necrosis rate 0.1030 1/day
𝑏𝜅 Modified inhibition rate 1.0839 ⋅ 10−6 mg/(ml⋅day)
𝑥1(0) Initial proliferating tumor volume 49.0497 mm3
𝐾𝐵 Michaelis-Menten constant of the inhibitor 0.4409 mg/ml
ED50 Median effective dose of the inhibitor 50 ⋅ 10−6 mg/ml
Thedynamics of the output is described by the differential
equation
̇𝑦 = 𝑎𝑥1 (8)
that is the sum of (4) and (5); thus the change of the
measured tumor volume depends only on the tumor growth
rate constant 𝑎 and the actual volume of the proliferating
tumor volume.
We will use the method discussed in [23] to show that
this model is nonnegative; that is, for nonnegative initial
conditions and nonnegative input, the solution of the differ-
ential equation is always nonnegative. It was shown in [23,
Proposition 2.1] that the dynamical system is nonnegative if
and only if the vector field corresponding to the right-hand
side of the differential equation of the dynamical system is
essentially nonnegative. A vector field is said to be essentially
nonnegative if its 𝑖th component is nonnegative whenever the
𝑖th state variable is zero and all other states are nonnegative.
The vector field defining the dynamics of the system given
by the right-hand sides of (4)–(6) is essentially nonnegative,
since
(i) ?̇?1|𝑥1=0 = 0; thus the first component of the vector
field is nonnegative if 𝑥1 = 0;
(ii) ?̇?2|𝑥2=0 = 𝑛𝑥1 +𝑏(𝑥1𝑥3/(ED50 +𝑥3)) ≥ 0, if 𝑥1, 𝑥3 ≥ 0;
(iii) ?̇?3|𝑥3=0 = 𝑢 ≥ 0, if 𝑢 ≥ 0.
Thus the system with dynamics defined by the differential
equations (4)–(6) is nonnegative. Note that here we have
supposed that 𝑢 ≥ 0 which is based on the physiological
consideration that we can not take out drug from the patient,
so the input can not be negative in practice; however it could
be negative theoretically.
4. Results of the Parametric Identification
The parametric identification has been carried out using
experimentsmadewithmice, for the details of the experiment
see [17]. The C57Bl/6 mice with C38 colon adenocarcinoma
were treated with bevacizumab using two different therapies.
(i) Therapy 1. Five mice (mouse C1–C5) got an injection of
0.171mg/ml bevacizumab at the beginning of the treatment
(Figure 1(a)).
(ii) Therapy 2. Nine mice (mouse E1–E9) got 9.5 ⋅ 10−4mg/ml
injection of bevacizumab each day for 18 days (Figure 1(b)).
The parametric identification was done using a combi-
nation of random and gradient-based search algorithm with
more than 100000 runs that aimed to minimize the distance
of the simulated total tumor volume and themeasured tumor
volumes in the least squares sense. The parameters that
resulted in the smallest least squares error are presented
in Table 1. Note that the median effective dose (ED50) of
the inhibitor was not identified; this value is given for
bevacizumab in [22]. The initial proliferating tumor volume
𝑥1(0) was identified as a parameter; this value is the initial
value for the proliferating tumor volume in the simulations,
while we suppose that initially the necrotic part has zero
volume. We use this assumption since in the experiments
morphologically homogeneous cancer cells were implanted
subcutaneously that have no necrotic part [24].
The simulated total tumor volumes for Therapy 1 and for
Therapy 2 are shown along with the measurements and their
average in Figures 1(a) and 1(b), respectively. The simulated
therapies using the model with the identified parameters
show a good fit for the measurements in the least squares
sense; they are close to the average of themeasurements. Since
therewere ninemice forTherapy 2 and only five forTherapy 1,
but the measurements were used with the same weight in the
identification process, the resulting outcome is closer to the
average of the measurements frommice E1–E9 (that received
Therapy 2). Note that the average is only valid at the time
of measurements (denoted by thick dots); the dotted curve
is just a linear interpolation and is used for visual clarity. It
should be emphasized that the quantities shown in Figures
1(a) and 1(b) are the total tumor volumes, that is, the sum of
the proliferating and necrotic tumor volumes (𝑥1 + 𝑥2).
Figure 2(a) shows the total tumor volume and necrotic
tumor volume as a result of the simulation of Therapy 1. The
final total tumor volume is 4741mm3, with 1529mm3 necrotic
part. Figure 2(b) shows the total tumor volume and necrotic
tumor volume as a result of the simulation of Therapy 2. The
final tumor volume in this case is 3713mm3 with 1931mm3
necrotic part.
Figure 3(a) shows the inhibitor serum level as a result
of the simulation of Therapy 1. The inhibitor serum level is
initially 0.171mg/ml and decreases and depletes in about two
weeks. Figure 3(b) shows the inhibitor serum level as a result
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Figure 1: (a) The measured tumor volumes for mice C1–C5 that got Therapy 1 and their average, and the simulated tumor volume using
Therapy 1 with the identified model (solid curve). (b)Themeasured tumor volumes for mice E1–E9 that gotTherapy 2 and their average, and
the simulated tumor volume usingTherapy 2 with the identified model (solid curve).
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Figure 2:The simulated total tumor volume and necrotic tumor volume with parameters resulting after identification with (a)Therapy 1 and
(b) Therapy 2.
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Figure 3: The simulated inhibitor serum using the model with parameters resulting after identification for (a) Therapy 1 and for (b)Therapy
2.
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Table 2: The final total tumor volume, the final necrotic tumor volume, and the total amount of inhibitors used in Therapies 1 and 2 as a
result of simulation carried out with the extended tumor growth model using the parameters acquired after identification.
Therapy 1 Therapy 2
Final total tumor volume [mm3] 4741 3713
Final necrotic tumor volume [mm3] 1529 1931
Total used drug [mg/ml] 0.171 0.0171
Tumor
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Figure 4: Compartment model of the extended tumor growth model. Gray items represent additional information to the biological
background of the process which are not explicitly described in the model but included with Michaelis-Menten kinetics and thus cause
the nonlinearities.
of the simulation of Therapy 2. The inhibitor serum level is
initially 9.5 ⋅ 10−4mg/ml, decreases on a certain time interval,
but gets refilled each day due to the daily injections. Initially,
the mean of the inhibitor serum level increases, but it starts
to decrease as the proliferating tumor volume grows.
The simulated final tumor volumes and total amount of
used drugs for the two therapies are shown in Table 2. The
simulation results show that the application of Therapy 2
results in much lower tumor volume than the application of
Therapy 1 using ten times less drug, as it was shown in [17].
5. Discussion
A key factor of angiogenesis is VEGF (vascular endothelial
growth factor). Bevacizumab inhibits VEGF-induced pro-
liferation of endothelial cells [25]. The clearance of beva-
cizumab is a complex process which depends on several fac-
tors, namely on bodyweight, gender, serum albumin, alkaline
phosphatase (ALP), and serum aspartate aminotransferase
(AST) [26, 27]. In our previous mice experiments [17] all
mice were 20 gram male C57Bl/6 mice. Since our aim was
to create the most compact model possible, it is out of
our scope to incorporate effects like serum albumin, ALP,
and AST changes. However, the clearance of bevacizumab
also depends on the tumor burden. Patients with a lower
tumor burden have a lower clearance rate [28, 29] which
was important to be modeled. The estimated clearance of
bevacizumab is 0.207 1/day (95% CI, 0.188–0.226 1/day) [26].
The clearance parameter was identified as 0.1825 1/day in the
extended tumor growth model.
Another notable phenomenon is the metabolic profile of
bevacizumab that was found to be similar to a native IgG
(ImmunoglobulinG antibody)molecule which does not bind
VEGF [30]. The major histocompatibility complex (MHC)
class I-related receptor FcRn (neonatal Fc Receptor), which
can be found in the endothelium of small arterioles and
capillaries, modulates IgG trafficking across tissues [31] and
hence plays a major role in the clearance of bevacizumab
as well. Serum bevacizumab has two depletion ways (Fig-
ure 4). The evident process is the binding to cell surface
receptors; this is the drug’s mechanism of action, namely,
inhibition of angiogenesis, leading to necrotic tumor cells.
This process was modeled with Michaelis-Menten kinetics
using median effective dose ED50, resulting in the term?̇?3 = −𝑏𝜅𝑥1𝑥3/(ED50 + 𝑥3). The reaction rate of binding to
cell surface receptors is 𝑏 (𝑏𝜅 = 𝜅𝑏). The other depletion
way is the bulk phase nonspecific endocytosis [32] which is
the uptake of extracellular bevacizumab via pinocytosis into
endosomes of catabolic cells where it binds to FcRn [33].
This binding protects bevacizumab from degradation and
systemic elimination and indicates recyclation to the serum,
accounting for the longer half-life of the angiogenic inhibitor.
This process was modeled with Michaelis-Menten mixed-
order model, resulting in the term ?̇?3 = −𝑐𝑥3/(𝐾𝐵 + 𝑥3). The
reaction rate of internalization into endosome is 𝑐.
Cancers are not composed of homogeneous cell groups
but rather contain different subpopulations of tumor cells.
There are active, proliferating cells (typically these cells are
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located on the surface of the tumor or near living/nascent
vessels) but inactive cells are present as well. Most of the
inactive cells have died, for example, due to hypoxia; these
cells form necrotic regions; however, there are special types
of tumor cells which are only temporarily inactive and have
propagating potential. These quiescent cells are also known
as cancer stem or stem-like cells. Cancer stem cells are in a
reversible G0 phase from which these cells may escape on
account of specific signaling pathways and molecules like
tumor protein p53, retinoblastoma protein (RB), and cyclin-
dependent kinases inhibitors (CDKIs) [34]. The quiescent
cells can disseminate to distant locations causing tumor
dormancy even for long time periods. In addition, stem
cells also exist within the tumor leading to the ability of
resistance to conventional chemo- and radiotherapies [35].
In our experiment, C38 colon adenocarcinoma was used
as tumorous cell line which typically does not metastasize;
hence modeling disseminated quiescent cells would be inex-
pedient. Quiescent cells within the primer tumor have critical
role in conventional therapies (like chemotherapy), but their
role in antiangiogenic monotherapy is not clear. Cai et al.
[36] modeled the tumor growth and its microenvironment
in antiangiogenic therapy assuming four different tumor cell
phenotypes: proliferative cells, quiescent cells, necrotic cells,
and migrating cells. Their criterion for a quiescent cell is the
case when the tumor cell “satisfies the survival condition but
there is no neighboring space for it to proliferate” [36]. Upon
this unfavorable space condition ceases (and the oxygen
supply is sufficient), the quiescent cell will turn back into a
proliferating cell. In our experiment, due to the subcutaneous
localization of the tumors, these limiting space conditions
are not presumptive; therefore our extended tumor model
does not incorporate the effect of quiescent cells; we take into
account these cells as proliferating cells.
In the extended tumor growth model, the effect of
angiogenic inhibitor is taken into account as a direct effect
on tumor cells, instead of an indirect effect through the tumor
vasculature. The aim of this modeling approach is manifold.
On the one hand, our aim was to model tumor growth
taking into account the most important and separatable
effects. Previously we have found that vasculature volume
changes and tumor volume changes are hardly separatable
in time [37, 38], which implies that identification of the
parameters corresponding to vasculature dynamics is very
hard if measurements of tumor vasculature are not avail-
able. This would limit the future application of the tumor
growth model in model-based individual therapy, since the
identification of the parameters specific to a patient would
requiremeasurement of the vasculature of the patient’s tumor.
Here we have proposed a descriptive model that does not
require vasculature measurements for identification. On the
other hand, it was found that VEGF inhibition may have
direct effects on tumor cells that impair tumor growth and
metastasis [39]. Inhibiting vascular endothelial growth factor
receptor 1 (VEGFR1) blocked tumor cell migration, invasion,
and colony formation in human colon cancer cells [40].
Due to the pharmacodynamics of the drug, the effect of
the inhibitor on the tumor growth is limited. In order to
analyze this effect, we examine two extreme cases.
(1) There is no drug present, that is, 𝑥3 ≡ 0. In this case
the proliferating tumor volume dynamics is described
by
?̇?1 = (𝑎 − 𝑛) 𝑥1, (9)
and the solution to that differential equation for any
𝑡 ≥ 0 is
𝑥1 (𝑡) = 𝑥1 (0) exp ((𝑎 − 𝑛) 𝑡) . (10)
Using the parameter values from Table 1, the pro-
liferating tumor volume for positive times without
treatment is given by
𝑥1 (𝑡) = 𝑥1 (0) exp (0.3549𝑡) . (11)
(2) The serum level of the drug is high; consider the case
𝑥3 →∞. Due to the pharmacodynamics, the value of
the term in (4) describing the effect of the drug is
lim
𝑥3→∞
𝑥3
ED50 + 𝑥3 = 1, (12)
and thus the proliferating tumor volume dynamics is
described by the differential equation
?̇?1 = (𝑎 − 𝑛 − 𝑏) 𝑥1, (13)
and the solution of this equation for 𝑡 ≥ 0 is
𝑥1 (𝑡) = 𝑥1 (0) exp ((𝑎 − 𝑛 − 𝑏) 𝑡) . (14)
Using the parameter values from Table 1, the prolif-
erating tumor volume for positive times with infinite
serum level of the drug is given by
𝑥1 (𝑡) = 𝑥1 (0) exp (0.1864𝑡) . (15)
This implies that, for any positive time 𝑡 and positive serum
level 𝑥3(𝑡), the proliferating tumor volume 𝑥1(𝑡) is bounded
as
𝑥1 (0) exp (0.1864𝑡) ≤ 𝑥1 (𝑡) ≤ 𝑥1 (0) exp (0.3549𝑡) . (16)
The solution to (4) can be approximated as
𝑥1 (𝑡) = 𝑥1 (0) exp((𝑎 − 𝑛) 𝑡 − 𝑏 𝑥3ED50 + 𝑥3 𝑡) (17)
due to the small value of 𝑏𝜅 (thus in our approximation we
have neglected the effect of 𝑥1 on 𝑥3). This shows that the
tumor growth is described by an exponential curve and the
inhibitor modifies the rate of the growth.
As a consequence of (16), the applied drug can not stop
the growth of the tumor; however, it can decrease the tumor
growth rate resulting in longer survival. The tumor growth
can be stopped if and only if the parameters satisfy the
inequality
𝑎 − 𝑛 − 𝑏 ≤ 0. (18)
The values of the parameters in Table 1 do not satisfy this
inequality; thus the tumor growth can not be stopped. This
result implicates that in theory the tumor growth can be
stopped by
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(1) increasing the value of 𝑏, which could be done by
finding an angiogenic drug that is more effective;
(2) increasing the value of 𝑛, which could be done
by combining antiangiogenic therapy with other
therapies attacking the proliferating tumor, that is,
chemotherapy or radiotherapy.
The model behavior shows the known fact that beva-
cizumab can not stop tumor growth. Due to the best of the
author’s knowledge, this is the only tumor growth model
incorporating the effect of angiogenic inhibition that pos-
sesses this property. This model can be extended later to
incorporate the effect of other drugs applied in combined
therapy with bevacizumab, which is one of the main moti-
vations behind the research presented here.
Since the structure of the extended model is different
from the original minimal model presented in [13], the
comparison of the parameters resulting after identification
can not be done directly, only after some transformations
discussed below. Note moreover that identification was done
in both cases by minimizing the least squared error from
the measurements; in [13] only the measurements from mice
C1–C4 were used; however, here we have used measurements
from mice C1–C5 and E1–E9; thus the resulting parameters
are necessarily different.
First consider the tumor dynamics without drug. In the
minimal model [13], the tumor growth dynamics without
drug is described by ?̇?1 = 𝑎𝑥1 (consider (1) with 𝑥2 = 0),
while for the extendedmodel, the tumor growthwithout drug
is governed by ?̇?1 = (𝑎 − 𝑛)𝑥1 ((4) with 𝑥3 = 0). The tumor
growth rate for the minimal model is 0.27 1/day, while the
transformed “net” tumor growth rate for the extended model
is 𝑎 − 𝑛 = 0.3549 1/day.
Next, consider the effect of drug on the tumor growth
dynamics in the time instant when the first big dose injec-
tion (10mg/kg for the minimal model and the equivalent
0.171mg/ml serum level for the extended model) is given.
Denote the inhibition rate for the minimal model as 𝑏min,
while denote the inhibition rate for the extended model as
𝑏ext. Note that the dimension of 𝑏min is kg/(mg⋅day), while
the dimension of 𝑏ext is 1/day. When the injection appears,
the effect of the drug on the tumor growth dynamics is given
by 𝑏min𝑥110mg/kg for the minimal model and 𝑏ext𝑥1 for the
extended model (since 𝑥3/(ED50 + 𝑥3) = 0.171/(ED50 +0.171) ≈ 1). These effects are equivalent if we equate these
terms; thus 𝑏min𝑥110 = 𝑏ext𝑥1. This implies that the new
inhibition rate 𝑏ext should be compared to 10 times the old
inhibition rate, that is, 10𝑏min.The value of the new inhibition
rate is 0.1685 1/day, while 𝑏min ⋅ 10mg/kg = 0.074 1/day.
The values of the “net” tumor growth rate (𝑎 − 𝑛) and the
inhibition rate for the extended model are higher than the
values for the minimal model in [13]. In the identification
process for the extended model, measurements from mice
E1–E9 were also used, while for the minimal model, only
measurements from mice C1–C4 were used. Since for mice
E1–E9 the inhibitor input and the resulting tumor volume are
lower than for mice C1–C4; the inhibiting effect of the drug
is higher according to the extended model.
The values acquired after the identification describe the
average of the measurements and so the average of the
population, not the tumor growth dynamics in a specific
mice. However, with small perturbations in tumor growth
rate, necrotic rate, and inhibition rate, all the individual mice
measurements can be described with the proposed model. In
our future works, we will create a mixed-effect model [41];
that is, wewill determine the variance of the parameters based
on the measurements.
6. Conclusions and Future Works
We have shown that the extended model is able to describe
the most relevant physiological phenomena and explains the
measurements aswell.Themodel structurewas kept as simple
as possible; most of the terms in the differential equations
are linear, except for the pharmacodynamics and pharma-
cokinetics; however these nonlinear terms were necessary to
describe an important phenomenon recognized in [17] that is,
thatmuch smaller, butmore frequent doses aremore effective
than a great initial dose, regardless of the long depletion time
of the drug.
The simplicity however has a price: the dynamics of the
vasculature is not modeled. For a good model of vasculature
dynamics and the effect of inhibition on the tumor vascula-
ture, see [42]. Nevertheless, the results have shown that the
extended model can describe the tumor growth dynamics
efficiently even without modeling the vasculature; thus we
have neglected the vasculature dynamics (note that modeling
vasculature dynamics would increase the order of the system;
thus the model would be more complicated). Moreover,
experiments done with untreated tumor in [38] have shown
that tumor dynamics can be described with a first-order
model, implicating that tumor growth dynamics dominates
vasculature dynamics, which also implies that identification
of the parameters corresponding to vasculature dynamics is a
hard task or nearly impossible without having measurements
of the vasculature. Nevertheless, in our experiments, these
measurements were not available.
The structure of the model and the identified parameters
imply that the tumor growth can not be stopped using
bevacizumab as monotherapy; however, it can slow down the
tumor growth, as it turned out in clinical practice as well [22].
Based on the model, tumor growth can be stopped by either
finding a more effective drug or combining bevacizumab
treatment with other treatments.This is recognized in clinical
practice as well, since bevacizumab in combination therapy is
widely used recently [3].
Themain goal of the presented work is tomodel the effect
of bevacizumab on tumor growth; however the long-term
goal is to model the effect of therapies where bevacizumab is
combinedwith other drugs. Sincemodeling the effect of com-
bined therapies is challenging in many ways (identification,
experiment design, etc.), analyzing and modeling the effect
of bevacizumab only are beneficial; in this way its effect is
separated from the other drugs. In our future works, we will
extend the model presented here to be able to describe mixed
therapies. The presented model structure gives a good basis
for this extension.
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